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Angiogenesis is crucial for maintaining the supply of oxygen and nutrients required to support solid tumour growth. Inhibitors of
tumour blood vessel formation are therefore being sought, in particular, inhibitors of vascular endothelial growth factor-A (VEGF)-
signalling, which has a pivotal role in stimulating neovascular growth and survival. ZD6474 is an orally bioavailable inhibitor of VEGF
receptor-2 tyrosine kinase activity that in preclinical studies has been shown to inhibit both VEGF-induced signalling in endothelial cells
and tumour-induced angiogenesis. Consistent with inhibition of angiogenesis, once-daily oral dosing of ZD6474 produced significant
broad-spectrum antitumour activity in a panel of histologically diverse human tumour xenografts. In addition to its antiangiogenic
properties, ZD6474 also has activity against the epidermal growth factor receptor (EGFR) tyrosine kinase, which could impart a direct
inhibitory effect on tumour cell growth and survival. This may be particularly relevant in tumours with a dependency upon EGFR
signalling, for example in certain tumours harbouring activating mutations in EGFR. RET kinase has also been identified as a third target
for ZD6474. This review summarises preclinical studies with this unique agent and considers its future direction in cancer treatment.
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In order to grow beyond a few millimetres in size, tumours must
develop a functioning vascular network to provide essential
nutrients and oxygen. Early in tumorigenesis, an ‘angiogenic
switch’ occurs within the tumour microenvironment, which is
associated with the altered expression of a range of proangiogenic
growth factors, such as vascular endothelial growth factor-A
(VEGF) and basic fibroblast growth factor (bFGF). The resulting
imbalance of proangiogenic factors stimulates the sprouting of
new blood vessels from pre-existing vessels within the surrounding
normal tissue. These new vessels grow and infiltrate into the
tumour, providing nutrients and oxygen to sustain tumour
expansion, and a route for cancer cell dissemination. The carefully
controlled balance of pro- and antiangiogenic growth factors
during physiological angiogenesis (wound healing, menstrual cycle
and pregnancy) produces well-ordered vascular structures with
mature, functional blood vessels. In contrast, pathological
angiogenesis associated with tumour growth is characterised by
disorganised vasculature that lacks clear hierarchical organisation,
with associated abnormalities in blood flow, vascular permeability
and pericyte–endothelial cell interactions, and with a high fraction
of immature, proliferating endothelial cells.
While many factors have been implicated in promoting
angiogenesis, VEGF appears to play a pivotal rate-limiting role,
which has been attributed to its ability to regulate key steps in the
angiogenesis cascade, including inducing endothelial cell prolifera-
tion, migration, survival and capillary tube formation (Benjamin
et al, 1999; Yancopoulos et al, 2000; Jain, 2003; Ferrara, 2004).
Vascular endothelial growth factor also induces increased vascular
permeability, which is a characteristic of tumour neovasculature
(Senger et al, 1983; Dvorak et al, 1995). Vascular endothelial
growth factor mRNA is upregulated in human cancers, as a
consequence of oncogene activation, loss of tumour suppressor
function or hypoxia resulting from suboptimal perfusion (Shweiki
et al, 1995; Rak et al, 2000). High levels of VEGF receptor (VEGFR)
mRNA are also detectable in tumour-associated endothelial cells
(Brown et al, 1993a,b; Plate et al, 1994), and high circulating
plasma levels of VEGF have been shown to correlate with poor
prognosis in patients with a variety of solid malignancies (Poon
et al, 2001; Jubb et al, 2004).
Vascular endothelial growth factor binds to the receptors
VEGFR-1 (Flt-1) and VEGFR-2 (kinase insert domain-containing
receptor; KDR) on vascular endothelial cells. Significantly,
activation of VEGFR-2 alone is necessary and sufficient to effect
VEGF-induced mitogenesis, angiogenesis and vascular permeabil-
ity (Ferrara et al, 2003). Vascular endothelial growth factor
receptors are single-pass transmembrane receptors that possess
intrinsic receptor tyrosine kinase activity within the cytoplasmic
domain of the receptor. Ligand (VEGF) binding results in VEGFR
dimerisation, which in turn triggers kinase activation and
autophosphorylation of specific intracellular VEGFR tyrosine
residues. Autophosphorylation at these tyrosine residues further
increases the catalytic activity of the tyrosine kinase, and provides
potential docking sites for cytoplasmic signal transduction
molecules such as PLC-g (Matsumoto and Claesson-Welsh,
2001). These protein interactions are essential for mediating the
intracellular signalling that is required to induce cellular responses
to VEGF (for example, endothelial cell proliferation, survival and
migration).
Recognition of the key role of VEGF-mediated VEGFR-2
signalling in pathological angiogenesis has led to the development
of various targeted strategies designed to inhibit VEGFR-2
activation, which include ligand sequestration, receptor antagonist
approaches or receptor tyrosine kinase inhibition (Madhusudan *Correspondence: Dr SR Wedge; E-mail: steve.wedge@astrazeneca.com
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the latter has been approached by the development of small
molecule ATP-competitive inhibitors that are compatible with
long-term oral administration. Although ATP binding is a
common feature of the B518 protein kinases encoded by the
human genome, a small molecule inhibitor may interact with
nonconserved structural features within, or directly adjacent to,
the ATP binding site to attain kinase selectivity. By obstructing
ATP binding within a given kinase domain, the inhibitor prevents
the subsequent autophosphorylation that is mandatory for
initiating intracellular signal transduction (Noble et al, 2004).
ZD6474 is a novel heteroaromatic-substituted anilinoquinazoline
(Figure 1) that acts as a potent and reversible inhibitor of ATP binding
to VEGFR-2 tyrosine kinase. It was selected from a subseries of
compounds for further development after demonstrating nanomolar
inhibition of VEGFR-2 tyrosine kinase activity in vitro,c o m b i n e dw i t h
good oral bioavailability and sustained plasma drug levels supporting
once-daily oral therapy in vivo (Hennequin et al, 2002).
In addition, ZD6474 also inhibits epidermal growth factor
receptor (EGFR) tyrosine kinase activity. The EGFR autocrine
signalling pathway is central to cancer progression, and over-
expression of EGFR and/or its ligands, transforming growth factor
(TGF)-a and EGF has been reported in many human tumours
(Ciardiello and Tortora, 2001). The consequences of aberrant
EGFR tyrosine kinase activity include increased tumour cell
proliferation, survival and invasiveness (Salomon et al, 1995;
Perrotte et al, 1999), as well as the overexpression of proangiogenic
factors such as VEGF (Goldman et al, 1993; Gille et al, 1997). In
addition, inhibition of EGFR signalling has been shown to induce
selective apoptosis in tumour endothelial cells in an orthotopic
model of human renal cell carcinoma metastasis in bone (Weber
et al, 2003). It was postulated that some tumours may produce
high levels of EGFR ligands (TGF-a, EGF), thus stimulating EGFR
expression in tumour-associated endothelial cells and setting up a
paracrine endothelial cell survival signalling pathway that is
sensitive to inhibitors of EGFR signalling (Weber et al, 2003).
Consequently, ZD6474 has the potential to inhibit two key
pathways in tumour growth by (i) targeting tumour growth
indirectly, via inhibition of VEGF-dependent tumour angiogenesis
and VEGF-dependent endothelial cell survival, and (ii) targeting
tumour growth directly, via inhibition of EGFR-dependent tumour
cell proliferation and survival (Figure 1).
IN VITRO PRECLINICAL EVALUATION
Selective targeting of VEGFR and EGFR tyrosine kinase
activity
The ability of ZD6474 to inhibit tyrosine kinase activity was
determined using recombinant enzyme assays (Table 1; Wedge
et al, 2002). These studies identified ZD6474 as a potent inhibitor
of VEGFR-2 kinase activity (IC50¼40nM). Compared with the IC50
for VEGFR-2 kinase, ZD6474 was only 2.7-fold less active vs
VEGFR-3 (Flt-4) kinase, but demonstrated 40-fold selectivity vs the
kinase associated with VEGFR-1. Vascular endothelial growth
factor receptor-3 and its ligands (VEGF-C and VEGF-D) are known
to play key roles in the regulation of lymphangiogenesis (Jussila
and Alitalo, 2002). Although thought to be largely restricted to
lymphatic endothelium, VEGFR-3 expression has recently been
detected on the vascular endothelium of human tumours, most
notably in renal cell carcinoma, although the functional signifi-
cance of this remains to be determined (Bando et al, 2004). In
addition, there is emerging evidence from animal models that
VEGF-C overexpression may promote metastatic spread to lymph
nodes (Schietroma et al, 2003) and clinically, high expression of
VEGF-C and/or -D has been found to predict for nodal metastasis
and poor prognosis in a number of different tumour types
(Kurahara et al, 2004; Zeng et al, 2004; Suzuki et al, 2005).
Determining the relevance of ZD6474 inhibition of VEGFR-3
kinase activity in recombinant enzyme assays requires further
evaluation of receptor signalling in cellular assays.
ZD6474 was also shown to inhibit EGFR tyrosine kinase activity
in recombinant enzyme assays (IC50¼500nM), but demonstrated
excellent selectivity for VEGFR-2 kinase vs structurally related
receptor tyrosine kinases, such as c-kit, and kinases from other
families (Table 1).
Anti-EGFR effect
At the tumour cell, ZD6474 may:
Inhibit cell proliferation
Decrease invasion
Promote apoptosis
Inhibit metastasis
Decrease VEGF production
Anti-VEGFR-2 effect
At the endothelial cell, ZD6474:
Inhibits angiogenesis by
decreasing endothelial cell
proliferation and migration
Inhibits VEGF-dependent
endothelial cell survival
Decreases vascular
permeability
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Figure 1 ZD6474 chemical structure and mechanism of action.
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potent inhibitor of VEGF-stimulated human umbilical vein
endothelial cell (HUVEC) proliferation in vitro (IC50¼60nM)
(Wedge et al, 2002). In assays measuring inhibition of EGF-
stimulated HUVEC proliferation, ZD6474 was approximately
three-fold less potent (IC50¼170nM). In contrast, much higher
doses of ZD6474 were required to inhibit bFGF-stimulated HUVEC
proliferation (IC50¼800nM) or basal (serum-stimulated) HUVEC
proliferation (IC5043000nM). These data demonstrate that
ZD6474 is a selective inhibitor of VEGF- and EGF-stimulated cell
proliferation.
Direct inhibition of tumour cell growth – influence of
EGFR mutation
The primary antitumour effect of ZD6474 is considered to be via
inhibition of VEGFR tyrosine kinase activity in tumour endothelial
cells. However, in vitro evidence shows that ZD6474 can also elicit
direct inhibition of tumour cell growth (Arao et al, 2004). ZD6474
inhibited the growth of cell lines derived from various human
cancers, including lung, breast, ovarian and colon cancer. This
effect appeared to be via inhibition of EGFR tyrosine kinase
activity, since the relative IC50 values of ZD6474 matched those of
gefitinib, a specific inhibitor of EGFR tyrosine kinase. Among the
cell lines examined, one derived from a Japanese female patient
with adenocarcinoma of the lung (PC-9) was shown to be
hypersensitive to ZD6474 (IC50¼90nM for serum-stimulated
tumour cell growth). PC-9 has a 15bp deletion mutation in the
gene encoding the EGFR. The EGFR tyrosine kinase of this
mutated gene is active even in the absence of exogenously added
ligand, and is more sensitive to the inhibitory effects of ZD6474
than wild-type EGFR tyrosine kinase (Arao et al, 2004; Taguchi
et al, 2004). Overall, these results suggest that ZD6474 can inhibit
EGFR-dependent tumour growth, and also that the magnitude of
inhibition may depend upon the expression of mutant EGFR.
Additional activity vs RET kinase
ZD6474 has also demonstrated potent inhibition of ligand-
dependent RET receptor tyrosine kinase activity (IC50¼100nM)
and selective inhibition of RET-dependent thyroid tumour cell
growth in vitro (Carlomagno et al, 2002; Carlomagno et al, 2004).
ZD6474 inhibited the majority of mutated, activated forms of RET
receptor tyrosine kinase and also inhibited the wild-type enzyme.
Therefore, in addition to inhibition of VEGFR-2 tyrosine kinase
and EGFR tyrosine kinase, inhibition of RET tyrosine kinase by
ZD6474 may provide particular additional antitumour effects in
the treatment of tumours with genetic changes in the RET gene
(mutation or translocation) that lead to RET receptor signalling-
dependent tumour cell growth (Santoro et al, 2002).
IN VIVO PRECLINICAL EVALUATION
ZD6474 inhibits VEGF signalling, angiogenesis and
vascular permeability in vivo
The ability of ZD6474 to inhibit VEGF signalling selectively in vivo
was demonstrated in a hypotension assay in anaesthetised rat,
where a number of growth factors are known to induce acute
hypotensive changes by signalling through their cognate receptor.
In this model, ZD6474 showed reversal of hypotension induced by
VEGF, but did not significantly reverse hypotension induced by
bFGF (Wedge et al, 2002).
The effects of ZD6474 on epiphyseal growth-plate morphology
and ossification were also examined, since this is a physiological
process critically dependent upon angiogenic invasion into the
growth plate and VEGF-signalling within cellular subtypes to
regulate bone morphogenesis. Consistent with inhibition of VEGF
signalling, ZD6474 treatment inhibited ossification and produced a
dose-dependent increase in epiphyseal growth-plate hypertrophy
(Wedge et al, 2002).
Several preclinical studies have shown that ZD6474 inhibits
tumour angiogenesis in vivo. ZD6474 significantly inhibited new
blood vessel formation following intradermal transplantation of
human non-small-cell lung cancer (NSCLC) cells (Figure 2; Wedge
et al, 2002), and tumour microvessel density was reduced by
ZD6474 administration in orthotopic models of human gastric
(McCarty et al, 2004) and pancreatic cancer (Figure 3; Bruns et al,
2003). A striking observation in the gastric cancer model was the
increased proportion of pericyte-associated endothelial cells post-
ZD6474 treatment, despite a marked reduction in the overall
number of tumour endothelial cells. This finding is likely to be due
to an effect of ZD6474 on the survival of tumour blood vessels that
are not stabilised by perivascular support. A similar finding was
reported in human prostate cancer, with selective apoptosis of
perictye-free endothelial cells occurring after hormone-therapy-
induced loss of VEGF activity (Benjamin et al, 1999). Immature
blood vessels are known to be reliant on VEGF-induced survival
Table 1 ZD6474 kinase selectivity (adapted from Wedge et al, 2002)
Kinase IC50 (lM)
VEGFR-2 (KDR) 0.04
VEGFR-3 (Flt-4) 0.11
RET 0.13
EGFR 0.5
VEGFR-1 (Flt-1) 41
PDGFR-b 41
Tie-2 41
FGFR1 41
MEK 410
CDK2 410
c-kit 420
erbB2 420
FAK 420
PDK1 420
AKT 4100
IGF-1R 4200
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Figure 2 ZD6474 inhibits tumour-induced new blood vessel develop-
ment. A549 tumour cells were implanted intradermally and new blood
vessel formation was assessed after 5 days’ administration of ZD6474 (50
or 100mgkg
 1day
 1) or vehicle (Wedge et al, 2002).
ZD6474 inhibits VEGFR and EGFR tyrosine kinase activity
AJ Ryan and SR Wedge
S8
British Journal of Cancer (2005) 92(Suppl 1), S6–S13 & 2005 Cancer Research UKsignalling, probably mediated by the PI3K/AKT pathway (Gerber
et al, 1998).
Dynamic contrast-enhanced magnetic resonance imaging (DCE-
MRI) is a technique that can be utilised to measure tumour
haemodynamic parameters in vivo. DCE-MRI may therefore be
used to detect alterations in tumour vascular permeability and/or
perfusion in response to drug treatment. This technology is
currently being evaluated in clinical trials with VEGF signalling
inhibitors, since VEGF is known to enhance vascular permeability
significantly (Morgan et al, 2003; Willett et al, 2004). Encouraging
preclinical results have been obtained with ZD6474 in mouse
models of human prostate (Checkley et al, 2003) and colon
(Bradley et al, 2004) cancer. In both studies, DCE-MRI analysis
showed a dose-dependent reduction in contrast agent uptake by
tumours, 24h after initiating therapy with ZD6474. These results
are consistent with ZD6474 inhibition of VEGF-induced perme-
ability in tumour vasculature (Dvorak et al, 1995).
ZD6474 inhibits tumour growth in a wide range of models
ZD6474 has demonstrated broad-spectrum antitumour activity in
preclinical models. In a histologically diverse range of tumour
xenograft models (lung, prostate, breast, ovarian, colon or vulval),
chronic once-daily oral administration of ZD6474 at doses of
25 100mgkg
 1 produced significant, dose-dependent inhibition
of tumour growth (Figure 4; Wedge et al, 2002). Drug treatment
was well tolerated at doses of 100mgkg
 1day
 1 for up to 5 weeks.
The broad-spectrum activity observed with ZD6474 in tumour
models is consistent with inhibition of VEGF signalling and an
indirect (that is, antiangiogenic) antitumour effect rather than
direct antiproliferative effects on the tumour cell. To support this,
we have shown that tumour models that are known to be either
sensitive (for example, A431 and LoVo) or insensitive (for
example, PC-3 and Calu-6) to the selective EGFR tyrosine kinase
inhibitor gefitinib, are all sensitive to ZD6474 (Figure 4).
ZD6474 also displayed antitumour activity in a xenograft model
with acquired resistance to EGFR signalling inhibitors (Ciardiello
et al, 2004). The authors attributed this effect of ZD6474 to
inhibition of VEGF signalling, since in vitro data indicated that
VEGF expression was upregulated in EGFR inhibitor-resistant
cells. Gefitinib-resistant tumour cells were crossresistant to
ZD6474 in vitro, but not in vivo. This suggests that in these
tumour cells the in vitro antitumour activity of ZD6474 is
dependent on EGFR tyrosine kinase inhibition, whereas the in
vivo antitumour activity of ZD6474 is not. Collectively, these data
suggest that ZD6474 may be an effective treatment against tumours
with acquired or intrinsic EGFR resistance, because of its ability to
inhibit VEGF signalling. Nonetheless, additional inhibition of
EGFR tyrosine kinase may afford further therapeutic benefits,
depending upon the tumour type. To date, this has been most
profoundly shown in a preclinical in vivo study examining
established PC-9 human lung cancer xenografts. ZD6474 (12.5–
50mgkg
 1day
 1) caused robust regression of PC-9 tumours at all
Figure 3 ZD6474 reduces tumour microvessel density. Intravital
microscopy image taken in mice with L3.6pl pancreatic tumours growing
in dorsal skin-fold chambers after 6 days’ treatment with ZD6474
(50mgkg
 1day
 1) (Figure provided by CJ Bruns).
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Figure 4 Antitumour efficacy of ZD6474 in a range of tumour types (adapted from Wedge et al, 2002).
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cells harbour an activating mutation of the EGFR gene and are
highly sensitive to ZD6474 treatment in vitro. Therefore, in tumour
cells that are highly dependent on EGFR signalling for continued
proliferation and survival, direct tumour cell effects may
contribute significantly to the in vivo antitumour activity of
ZD6474.
ZD6474 has also been shown to inhibit growth of tumours
implanted orthotopically (that is, implantation at the tissue/organ
site from which the tumour originated). Organ–tumour interac-
tions at the site of the primary tumour and at the site(s) of
metastasis are considered important determinants of tumour
growth and development in man. Therefore, it has been suggested
that orthotopically implanted tumours may recapitulate the
natural tumour setting more accurately than subcutaneous models
(Taghian and Suit, 1999). In orthotopic models of gastric and
pancreatic cancer, ZD6474 administration significantly inhibited
tumour growth and increased tumour cell apoptosis (Bruns et al,
2003; McCarty et al, 2004). Almost complete suppression of
tumour growth and angiogenesis was also observed with ZD6474
treatment in orthotopic models of lung cancer (Wu et al, 2003,
2004).
The effect of ZD6474 in early tumorigenesis has been
investigated further in multiple intestinal neoplasia (Min) mice,
which develop spontaneous early intestinal adenomas (Wilkinson
et al, 2004). ZD6474 treatment (50mgkg
 1day
 1 for 4 weeks)
produced a 75% reduction in overall tumour burden compared
with vehicle treated controls (18.375.6 vs 76.5711.7mm
3,
P¼0.005), suggesting that ZD6474 could be an effective treatment
for early-stage disease. Indeed, early administration of ZD6474 has
also been shown to significantly inhibit mammary tumour
formation in a 7,12-dimethylbenz[a]anthracene model of breast
cancer in Sprague–Dawley rats (Heffelfinger et al, 2004).
ZD6474 inhibits tumour metastasis
The growth of both primary tumours and metastases are
dependent on the development of new blood vessels (Folkman,
2002). In addition, the aberrant, disorganised tumour vasculature
provides a route whereby tumour cells can escape the primary
tumour mass and disseminate to distant metastatic sites. In a
model of liver metastasis, ZD6474 treatment resulted in a
significant reduction in metastatic blood flow and a diminished
metastatic burden (Varghese et al, 2003). ZD6474
(50mgkg
 1day
 1) has also been shown to inhibit the production
of lung metastases in an orthotopic model of renal cell carcinoma
(Drevs et al, 2005). Similarly, lung and lymph node metastases
were seen to be reduced following ZD6474 treatment in a
metastatic human pancreatic tumour model (Bruns et al, 2003).
While speculative, it is not inconceivable that ZD6474 activity vs
VEGFR-3 tyrosine kinase could have contributed to the observed
reduction in lymphatic metastasis, particularly since approaches
that selectively inhibit activation of either VEGFR-2 or EGFR did
not inhibit lymph node metastases significantly in this model
(Bruns et al, 2000, 2002). Daily oral dosing with ZD6474 has also
been found to inhibit metastasis from established lung tumours
(Wu et al, 2004) and to limit the growth of NSCLC metastases
(Matsumori et al, 2003). Overall, these data demonstrate that
ZD6474 has the potential to inhibit metastasis by prevention of
primary tumour dissemination, as well as by inhibiting the growth
of any secondary tumours that become established.
ZD6474 in combination with other anticancer therapies
The results of a number of preclinical studies suggest that
combining ZD6474 with certain anticancer strategies may yield
additional therapeutic benefits. In a xenograft model of colon
cancer, ZD6474 (100 or 150mgkg
 1dose
 1) combined with the
conventional cytotoxic agent paclitaxel (20mgkg
 1dose
 1) pro-
duced a greater inhibition of tumour growth than that seen with
either agent alone (Figure 5; Ciardiello et al, 2003).
Studies have also investigated the efficacy of combining ZD6474
with radiotherapy in vivo. Vascular endothelial growth factor is an
important survival factor for endothelial cells, and inhibition of
VEGF signalling may augment the effects of ionizing radiation by
preventing VEGF-mediated recovery of damaged endothelial cells
(Gorski et al, 1999). Concurrent administration of ZD6474 and
radiation therapy in two xenograft models of lung cancer showed
greater antitumour effects compared with radiation therapy alone
(Hoang et al, 2004). The impact of scheduling ZD6474 and
radiation therapy has been investigated in Calu-6 xenografts
(Williams et al, 2004). Any inhibitory effect of ZD6474 in this
tumour model can be considered to be a function of its anti-
VEGFR activity, since tumour growth was unresponsive to a
specific inhibitor of EGFR tyrosine kinase. The study compared the
effects of radiotherapy in combination with concurrent or
sequential ZD6474 administration. Both combination schedules
significantly enhanced treatment efficacy compared with radio-
therapy or ZD6474 alone, but administration of ZD6474 after
radiotherapy was more effective than concurrent treatment.
Irradiation is known to cause transient tumour hypoxia, which
in turn induces VEGF expression (Gorski et al, 1999). The greater
efficacy observed in combination may possibly be attributed to
ZD6474 inhibiting the VEGF-dependent survival of endothelial
cells when administered after radiotherapy.
ZD6474 has also been examined in combination with SC-236, a
selective cyclooxygenase-2 (COX-2) inhibitor, in human xenograft
models of lung and colon cancer (Tuccillo et al, 2005). Over-
expression of COX-2 has been linked with promotion of tumour
cell growth and angiogenesis in human cancer (Masferrer et al,
2000; Masunaga et al, 2000). Combined ZD6474 and SC-236
treatment caused a supra-additive inhibition of established tumour
growth in both models, further demonstrating the potential for
ZD6474 to act in concert with other cancer treatments.
CONCLUSIONS AND FUTURE PERSPECTIVES
ZD6474 is a potent inhibitor of VEGFR-2 tyrosine kinase activity
and has demonstrated antitumour effects in a range of subcuta-
neous xenograft, orthotopic and metastatic preclinical tumour
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Figure 5 Antitumour activity of ZD6474 in combination with paclitaxel
on established GEO xenografts. After inoculation with GEO cells, mice
were treated on days 1–5 of each week for 4 weeks with ZD6474 (100 or
150mgkg
 1day
 1), alone or in combination with paclitaxel
(20mgkg
 1dose
 1) on day 1 of each week for 4 weeks (Ciardiello et al,
2003).
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resistance. This spectrum of activity is consistent with an
antiangiogenic mode of action, mediated through inhibition of
VEGFR tyrosine kinase activity in tumour-associated endothelial
cells. The clinical value of VEGF inhibition in the treatment of
cancer has already been demonstrated unequivocally with
bevacizumab, an anti-VEGF monoclonal antibody, when used in
combination with conventional chemotherapy in patients with
colorectal cancer (Hurwitz et al, 2004). ZD6474 may also benefit
from inhibiting EGFR tyrosine kinase in tumour cells with a
dependency upon EGFR signalling for survival or proliferation.
That inhibition of both VEGFR and EGFR signalling may
contribute to the net antitumour activity of ZD6474 represents
an interesting and unique profile amongst molecular targeted
therapies.
Achieving an optimal clinical response to ZD6474 may depend
on several factors. These include its use in combination with other
anticancer strategies and the stage of tumour development when
treatment is initiated. In vivo preclinical studies indicate that the
antitumour effects of ZD6474 are enhanced when it is used in
combination with certain chemotherapies. This is being investi-
gated further in ongoing phase II clinical trials of ZD6474, in which
patients with a range of tumour types will receive ZD6474 alone or
in combination with certain conventional cytotoxic agents.
Promising preclinical results have been obtained using ZD6474
in combination with radiotherapy, with the important caveat that
optimal efficacy may be dependent upon the schedule of
administration. Preliminary evidence is also emerging that
suggests tumour susceptibility to ZD6474 may be influenced by
mutations in the biological targets within the tumour (EGFR,
RET). Further mutational analysis of both EGFR and RET may be
necessary to better understand the clinical significance of this
phenomenon.
The activity of ZD6474 against RET kinase provides an
opportunity to target specific patient subsets who may obtain
particular benefit from this pharmacological activity. The RET
gene can be activated by somatic rearrangements in papillary
thyroid carcinoma or by point mutations in sporadic and familial
(MEN2) medullary thyroid carcinomas. Therefore, ZD6474 might
be especially beneficial in the treatment of thyroid tumours with
known mutations in the RET gene (Santoro et al, 2002). In these
cases, the combined effect of targeting RET and EGFR in the
thyroid cancer cells, and targeting VEGFR-2 in the tumour
vasculature may provide distinct advantages, and offer a focused
route for translating the unique profile of this agent into a
meaningful treatment for patients.
In conclusion, ZD6474 is a potent, orally bioavailable inhibitor
of VEGFR and EGFR tyrosine kinase activity. It is a novel
molecular-targeted agent that has shown promising antitumour
activity in preclinical models. Given early reports of clinical
activity with this agent in NSCLC (Minami et al, 2003), results
from additional clinical studies that will evaluate ZD6474 either as
monotherapy or in combination with established therapeutic
modalities, are eagerly awaited.
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